A Phase 1b/2, Multicenter, Open-label Study of S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors - aCCeleR8-001

agata Tsutae0 个研究点目标入组 54 人开始时间: 2021年11月12日最近更新: 2023年10月17日

适应症

试验速览

阶段: 1 期
状态: 招募中
发起方
入组人数: 54

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 20age old 至 ot applicable（—）
性别: All

入选标准

•1. Male or female participant must be at least 18 years of age inclusive (or complies with country-specific regulatory requirements, at least 20 years of age in Japan), at the time of signing the informed consent.
•2. Participants with histologically or cytologically confirmed advanced (locoregionally recurrent, not amenable to curative therapy) or metastatic solid tumors who have no standard therapies with a proven clinical benefit, or who are intolerant to or unwilling to receive these therapies for any reasons.
•3. Measurable disease by RECIST 1.1.
•4. (Part A only) Participants should have 1 of the following tumor types: malignant melanoma (MEL), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC), urothelial carcinoma (UC), nonsmall cell lung cancer (NSCLC), or triple-negative breast cancer (TNBC), esophageal cancer (EC; esophageal squamous cell carcinoma and adenocarcinoma), or gastric cancer (GC; gastric and gastroesophageal junction adenocarcinoma).
•5. (Part B only) Participants should have 1 of specific histologically or cytologically confirmed tumor types selected by the sponsor after completion of Part A-1.
•6. (Part C only) Participants should have 1 of specific histologically or cytologically confirmed tumor types selected by the sponsor after completion of Part A-2.
•7. Participants should be willing and able to provide permission to access archival formalin-fixed paraffin-embedded (FFPE) tumor tissues (as block or unstained slides) for this study.
•8. Participants should be willing and able to provide both pre-treatment and on-treatment paired tumor biopsy samples.
•9. (At selected sites only) Participants should be willing and able to provide both pre-treatment and on-treatment paired tumor biopsy samples. Fresh tissue samples are required as these will be used for the proof of mechanism analysis.
•10. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
•11. An estimated life expectancy of at least 12 weeks.
•12. Adequate hematologic and organ function as confirmed by laboratory values.
•13. QT interval corrected with the Fridericia formula (QTcF) < = 480 milliseconds in 12-lead electrocardiogram (ECG) at Screening.

排除标准

•1. Presence or history of autoimmune diseases or immune-mediated diseases that require chronic use of systemic corticosteroids (> 10 mg of prednisone equivalent per day), immunosuppressive agents, or diseasemodifying agents.
•2. Active clinically significant bacterial, viral or fungal infection, or any major episode of infection requiring hospitalization or treatment with parenteral antiinfectives within 4 weeks before the first dose of study intervention.
•3. Uncontrolled or clinically significant cardiovascular disease defined as New York Heart Association (NYHA) classification III or IV.
•4. A positive test for hepatitis B surface antigen (HBsAg) and/or hepatitis C virus (HCV) antibody (a confirmatory HCV RNA test if HCV antibody was positive).
•5. A positive serological test for human immunodeficiency virus (HIV) infection.
•6. Known history of any other relevant congenital or acquired immunodeficiency.
•7. Known history of severe allergy, hypersensitivity, anaphylaxis, or any serious adverse reaction to any component of study intervention or formulation components and/or any other monoclonal antibodies.
•8. Women who are pregnant or breastfeeding or trying to become pregnant.
•9. Clinical evidence of uncontrolled brain metastasis.
•10. Clinical evidence of any active second invasive malignancy (except stable prostate cancer on watchful waiting).
•11. (Parts A-2 and C only): Participants who developed an immunerelated adverse event (irAE) during prior pembrolizumab treatment that required a delay in the scheduled administration for more than 4 weeks due to any grade of irAEs or led to permanent discontinuation of pembrolizumab. Also, participants whose previous irAE due to pembrolizumab has not resolved to <= Grade 1 and/or still requires corticosteroids (> 10 mg of prednisone-equivalent per day).
•12. Prior treatment with systemic anticancer drugs (including any investigational medicinal products) within 28 days or 5 half-lives (whichever is shorter) before the first dose of study intervention.
•13. Prior major surgery within 28 days before the first dose of study intervention.
•14. Prior extended field radiotherapy within 28 days before the first dose of study intervention (within 14 days for limited field radiation for palliation).
•15. Participants who have not recovered from any previous treatment toxicities to <= Grade 1 or baseline (except alopecia and peripheral neuropathy) before the first dose of study intervention.
•16. Prior treatment with anti-CCR8 antibody for any indication.
•17. Receipt of a live, attenuated vaccine within 28 days before the first dose of study intervention.

研究者

发起方

agata Tsutae

相似试验

进行中（未招募）

不适用

A Phase 2, Multi-Center, Open-label Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2, 6-Month Schedule and of a Single dose of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy At-risk Adults 18-50 Years of Ageno medical, conditionhealthy, at risk volunteers will be recruited for a clinical trial to receive three vaccinations against meningococcal strain B and one vaccination against meningococcal strains A,C, W and Y.

EUCTR2007-001563-29-DEovartis Vaccines and Diagnostics S.r.l.250

进行中（未招募）

不适用

A Phase 2, Multi-Center, Open-label Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2, 6-Month Schedule and of a Single dose of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy At-risk Adults 18-50 Years of Age - NDPrevention Meningitis/Sepsi caused by Meningococcus type B or A, C, W-135, YMedDRA version: 9.1Level: SOCClassification code 10021881Term: Infections and infestations

EUCTR2007-001563-29-ITOVARTIS VACCINES AND DIAGNOSTICS S.R.L.250

进行中（未招募）

1 期

An Open-Label, Multicenter, Phase 2 Study of the Safety and Efficacy of KRT-232 in Subjects with Relapsed or Refractory Small Cell Lung Cancer (SCLC)

EUCTR2021-001530-19-HUKartos Therapeutics, Inc.56

进行中（未招募）

1 期

An Open-Label, Multicenter, Phase 2 Study of the Safety and Efficacy of KRT-232 in Subjects with Relapsed or Refractory Small Cell Lung Cancer (SCLC)Subjects with Relapsed or Refractory Small Cell Lung Cancer (SCLC)MedDRA version: 20.0Level: LLTClassification code 10025044Term: Lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10041067Term: Small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10041070Term: Small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2021-001530-19-ESKartos Therapeutics, Inc.56

进行中（未招募）

1 期

EUCTR2021-001530-19-DEKartos Therapeutics, Inc.56